Expression of B7-H3 and B7-H4 in Gastric Gastrointestinal Stromal Tumors.
| Autor: | Mochizuki K; University of Yamanashi, Chuo, Yamanashi, Japan., Oishi N, Tahara I, Inoue T, Kondo T |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2024 Nov-Dec 01; Vol. 32 (10), pp. 484-487. Date of Electronic Publication: 2024 Oct 02. |
| DOI: | 10.1097/PAI.0000000000001227 |
| Abstrakt: | Gastric gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms with variable behavior characterized by differentiation toward the interstitial cells of Cajal occurring anywhere in the gastrointestinal stromal tract. The management of GIST was revolutionized by the introduction of imatinib, a KIT inhibitor, which has become the standard first-line treatment for metastatic GIST. However, despite a clinical benefit rate of 80%, the majority of patients with GIST experience disease progression after 2 to 3 years of imatinib therapy. This shows the need for novel treatment approaches for imatinib refractory GISTs. The checkpoint proteins B7-H3 and B7-H4 inhibit the activation and function of T cells by potently suppressing the proliferation, cytokine production, and cytotoxicity of activated T cells, which is a mechanism for immune escape. This study aims to clarify B7-H3 and B7-H4 expression in gastric GISTs using immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR). We confirmed B7-H3 expression (H-score ≥50 points) in 92% and B7-H4 expression in 0% of GIST samples. We examined B7-H3 mRNA expression in 3 representative GIST samples, each having their respective immunostained areas detected by RT-PCR. B7-H3 is expressed at a particularly high rate in GISTs. This suggests that B7-H3 might operate as part of an immune checkpoint in GISTs. Competing Interests: The authors declare no conflict of interest. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|